Targeting cancer at the molecular level.
Our oncology pipeline is focused on the discovery and development of next-generation therapies that harness the immune system and target tumor-specific vulnerabilities.
We are pioneering a multi-modal approach to treating cancer. By identifying specific genetic mutations and protein expressions within tumor cells, we design targeted small molecules and antibody-drug conjugates (ADCs) that strike with precision, minimizing damage to healthy tissue.
Reactivating the body's natural defense systems to recognize and destroy cancer cells.
Modulating the surrounding cellular environment to prevent tumor growth and metastasis.
Exploiting specific genetic defects in cancer cells to induce cell death.
Animation
Our research engine is focused on high-value targets with the potential to transform standard of care.
A novel checkpoint inhibitor designed to have higher affinity and reduced immune-related adverse events.
Solid Tumors
Targeting the "undruggable" KRAS mutation with a highly selective small molecule inhibitor.
NSCLC / Colorectal
Next-generation Antibody-Drug Conjugate utilizing a cleavable linker for targeted delivery of potent payloads.
Breast / Ovarian
We are actively seeking collaborations to accelerate the development of transformative cancer therapies.